What is Cartalax 20MG

Cartalax 20MG is a short bioregulator peptide of the Khavinson class studied in research for its ability to stimulate cartilage and bone tissue regeneration. It is intended exclusively for research use.

Regarding its chemical identity, Cartalax has a molecular formula of C14H24N4O7 and a molecular weight of 360.4 g/mol. Its reported canonical sequence is Ala-Glu-Asp. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Cartalax.

Product for research use.

Mechanism of action of Cartalax

Cartalax functions by interacting directly with the DNA of chondrocytes and fibroblasts, regulating the synthesis of specific proteins necessary for the extracellular matrix of cartilage and bone. This leads to increased cellular proliferation and tissue repair in joints.

Pharmacokinetics and pharmacodynamics of Cartalax

Like other short bioregulators, Cartalax exhibits an extremely short plasma half-life, being rapidly cleaved by peptidases. Its mechanism relies on quick entry into the nucleus of target cells to exert long-term epigenetic modifications rather than sustained receptor binding.

Scientific evidence on Cartalax

The available evidence on Cartalax is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

The literature describes it as having been investigated for indications related to osteoarthritis, spinal osteochondrosis, and general joint degeneration in preclinical models. Its ability to restore cartilage elasticity without adverse inflammatory responses is a primary focus of study.

Cartalax applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Cartalax protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Cartalax, so no trial schemes or quantities are specified.

The presentations of this product (20MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Cartalax

As a general guideline for laboratory handling, lyophilized peptides such as Cartalax are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 20MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Cartalax Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Cartalax security profile

The documented safety information in open sources for Cartalax is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Due to its highly specific action on cartilage and connective tissue, systemic off-target effects are rarely documented. However, its safety profile remains largely theoretical and unverified in comprehensive clinical trials.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Cartalax in a comparative context

Cartalax shares the same developmental origins as other Khavinson peptides but is distinct in its tropism for chondrocytes. Compared to standard joint supplements like glucosamine, Cartalax acts at an epigenetic level to stimulate de novo protein synthesis.

History and development of Cartalax

Developed by Vladimir Khavinson, Cartalax was synthesized based on the amino acid analysis of natural extracts from animal cartilage. It has been studied primarily in Eastern European research contexts for age-related joint degradation.